Egrifta (Tesamorelin) Legal and Patent Challenges: FDA Approval, Labeling, and Safety

FDA Approval History and the NDA Pathway

Theratechnologies submitted NDA 022505 for tesamorelin under the standard 505(b)(1) pathway. The FDA approved Egrifta on November 10, 2010, making it the first and only approved pharmacotherapy specifically for HIV-associated lipodystrophy [1]. The approval was based primarily on two Phase 3 randomized controlled trials demonstrating statistically significant reductions in visceral adipose tissue (VAT).

The Key Phase 3 Evidence

The foundational efficacy data came from Falutz et al., published in the New England Journal of Medicine in 2007 [2]. That trial enrolled 412 HIV-infected adults with excess abdominal fat. Tesamorelin 2 mg/day reduced VAT by 15.2% from baseline compared with 1.5% in the placebo group at 26 weeks (P<0.001). Trunk fat measured by DEXA also fell significantly. Triglycerides dropped by a mean of 50 mg/dL in the tesamorelin arm versus a 6 mg/dL increase in placebo (P<0.001) [2].

A confirmatory 52-week extension of this work, along with a second Phase 3 trial of similar design, provided the package of data the FDA advisory committee reviewed in June 2010 [1]. The agency's complete response letter history and advisory committee transcript are available in the FDA's Drugs@FDA database for NDA 022505 [1].

Why the FDA Restricted the Label to One Indication

The Endocrinologic and Metabolic Drugs Advisory Committee voted 7-to-4 in favor of approval, with dissenting members citing concerns about off-label GH axis stimulation and cancer risk [1]. The FDA responded by writing a tightly scoped indication: "reduction of excess abdominal fat in HIV-infected patients with lipodystrophy." Use in non-HIV populations, age-related adiposity, or general growth hormone deficiency is not approved and would constitute off-label prescribing. The prescribing information explicitly states that "Egrifta is not indicated for weight loss management" [3].

Egrifta Label Requirements: What Clinicians Must Know

The current FDA-approved prescribing information for Egrifta (revised 2015 after the SV formulation approval) carries several clinically significant requirements [3]. These are not suggestions; deviating from them exposes prescribers to liability and patients to harm.

Contraindications

The label lists four absolute contraindications [3]:

• Active malignancy or a history of treated malignancy where there is clinical or biological evidence of disease
• Disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, or pituitary tumor
• Active proliferative or severe non-proliferative diabetic retinopathy
• Pregnancy

The malignancy contraindication is particularly significant given that HIV-infected patients on antiretroviral therapy carry elevated risks for certain non-AIDS-defining cancers [4].

Monitoring Requirements Written Into the Label

The FDA-approved label requires that IGF-1 levels be assessed before starting therapy and periodically thereafter [3]. If IGF-1 rises above age- and sex-adjusted normal ranges (generally above 2 standard deviations), the label recommends dose reduction or discontinuation. The prescribing information also instructs clinicians to monitor fasting glucose and HbA1c, because tesamorelin's GH-stimulating effect can induce insulin resistance [3].

A 2013 analysis published in the Journal of Clinical Endocrinology and Metabolism confirmed that tesamorelin raised IGF-1 by roughly 80 mcg/L from baseline in HIV-infected patients, a rise that persisted at 52 weeks [5]. That same analysis found a modest but statistically significant increase in fasting glucose of approximately 4 mg/dL, consistent with the label's warning [5].

The Egrifta SV Reformulation and 2015 Label Update

Theratechnologies launched Egrifta SV (a more stable, single-vial formulation) and obtained FDA approval for it in June 2019 under NDA 210730 [6]. The SV formulation uses a different reconstitution procedure and has a longer room-temperature stability window than the original lyophilized product. The prescribing information for Egrifta SV carries the same indication, contraindications, and monitoring requirements as the original, with updated storage and preparation instructions [6].

Patent Field and Hatch-Waxman Challenges

Theratechnologies has listed several patents in the FDA's Orange Book for both NDA 022505 and NDA 210730 [7]. The Hatch-Waxman Act allows generic manufacturers to file an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification, asserting that listed patents are either invalid or will not be infringed by the generic product.

Paragraph IV Certifications Filed Against Egrifta

As of the most recent Orange Book update, at least two generic applicants have filed Paragraph IV certifications against Egrifta patents [7]. Under Hatch-Waxman, when a brand-name company like Theratechnologies receives notice of a Paragraph IV certification, it has 45 days to file a patent infringement suit. Filing that suit automatically triggers a 30-month stay of FDA final approval for the generic, giving the innovator time to litigate [7].

The core patents protecting tesamorelin fall into two categories. Composition-of-matter patents cover the specific tesamorelin acetate peptide sequence. Method-of-use patents cover the therapeutic application to HIV-associated lipodystrophy specifically. Generic challengers have historically focused their invalidity arguments on prior art related to the broader class of GHRH analogs, given that the underlying peptide chemistry predates modern HIV therapy [8].

The Significance of Method-of-Use Patents

Method-of-use patents are generally considered weaker than composition-of-matter patents because a generic manufacturer can carve the patented indication out of its label (a so-called "skinny label" strategy). For Egrifta, where the HIV-lipodystrophy indication is the only approved use, a skinny label carve-out would leave a generic with no approved indication at all. This dynamic has complicated ANDA litigation and is one reason no generic tesamorelin had reached the U.S. Market as of early 2025 [7].

The HealthRX clinical-regulatory team has developed a decision framework for providers managing tesamorelin prescribing in the context of ongoing patent uncertainty. When a generic becomes available, clinicians should verify that the generic label carries the same contraindications and monitoring requirements as the brand, since skinny-label generics may omit HIV-lipodystrophy-specific safety language. Substitution should be confirmed with the dispensing pharmacist before the first fill.

International Patent Disputes and EMA Status

Tesamorelin does not hold EMA marketing authorization as of early 2025. The EMA has not approved any tesamorelin product for any indication, meaning the drug is not commercially available in the European Union through standard channels [9]. This absence of EMA approval has limited Theratechnologies' ability to assert parallel patent rights in EU member states, though the underlying composition-of-matter patents have been filed with the European Patent Office.

In Canada, Egrifta holds authorization from Health Canada (Drug Identification Number 02350092), and Theratechnologies has pursued patent protection under Canadian patent law [10]. Canadian patent litigation has mirrored U.S. Paragraph IV dynamics, with generic challengers arguing that the GHRH analog structure was not patentably novel over prior art.

Post-Market Safety Surveillance and FDA Obligations

FDA approval does not end regulatory obligations. Theratechnologies has fulfilled post-market commitments required under the original 2010 approval, including long-term cardiovascular outcome data and cancer incidence tracking in the treated HIV population [1].

IGF-1 Elevation and Cancer Risk: What Post-Market Data Show

The theoretical concern driving the 7-to-4 advisory committee vote in 2010 was that sustained GH/IGF-1 axis stimulation could promote malignancy. Post-market surveillance conducted through the FDA Sentinel system and company-sponsored registries has not identified a statistically significant increase in cancer incidence in tesamorelin-treated patients versus antiretroviral-treated HIV controls [1]. A 2019 observational analysis found no excess cancer signal over 3 years of follow-up in 892 tesamorelin-treated HIV patients, though the study acknowledged that longer follow-up was needed [11].

The Endocrine Society's clinical practice guideline on growth hormone deficiency in adults, published in the Journal of Clinical Endocrinology and Metabolism, states that IGF-1 levels above 2 standard deviations of the age-adjusted mean should prompt dose reduction of any GH-axis-stimulating agent [12]. Tesamorelin labeling directly incorporates this threshold [3].

Glucose and Metabolic Effects: Long-Term Data

Short-term trials consistently showed tesamorelin raised fasting insulin and marginally elevated fasting glucose [2, 5]. The 2019 post-market analysis found that new-onset diabetes mellitus developed in 7.4% of tesamorelin-exposed patients over 3 years, compared with 5.9% in a matched HIV-infected control group not receiving tesamorelin [11]. The absolute difference of 1.5 percentage points was not statistically significant at P = 0.12, but the trend supports the label's monitoring requirement for HbA1c [11].

Fluid Retention and Joint Complaints

GH-mediated fluid retention accounts for the most commonly reported adverse effects: peripheral edema (seen in roughly 6% of patients in Phase 3 trials), arthralgia (approximately 13%), and myalgia (approximately 6%) [3, 2]. These effects are generally dose-dependent and reversible on discontinuation. The label recommends assessing for pre-existing conditions that may be worsened by fluid retention, including congestive heart failure and renal insufficiency [3].

Off-Label Use, Prescribing Liability, and Compounding

Tesamorelin has attracted interest beyond its single FDA-approved indication. Clinicians in anti-aging medicine and sports performance medicine have asked about its use for general visceral fat reduction in non-HIV patients, growth hormone deficiency in adults without HIV, and cognitive function enhancement given early data suggesting GH axis effects on prefrontal cortex metabolism [13].

The Legal Risk of Off-Label Prescribing

Off-label prescribing is legal in the United States; the FDA regulates manufacturers, not physician practice [14]. However, Theratechnologies cannot legally promote Egrifta for indications outside HIV-associated lipodystrophy. Prescribers who use tesamorelin off-label assume clinical and medicolegal responsibility for any harm that results. Malpractice exposure is higher when the off-label use contradicts label contraindications, particularly the active malignancy restriction [14].

The FDA's guidance on industry promotion and off-label use, updated in 2023, clarifies that manufacturers may distribute reprints of peer-reviewed literature to healthcare professionals under defined conditions but cannot use sales representatives to actively promote unapproved uses [14].

Compounding Pharmacies and Tesamorelin

503A and 503B compounding pharmacies have prepared tesamorelin outside the approved NDA framework. The FDA's position is that compounding a copy of a commercially available approved drug without a valid individualized prescription and clinical rationale may constitute a violation of the FD&C Act [15]. The agency has sent warning letters to compounding pharmacies producing peptides including tesamorelin, citing concerns about sterility, potency, and the absence of an approved drug shortage designation [15]. Clinicians who prescribe compounded tesamorelin should be aware that the compounded product has not been reviewed for safety, efficacy, or manufacturing quality by the FDA [15].

Theratechnologies Corporate History and Regulatory Milestones

Theratechnologies is a specialty biopharmaceutical company founded in 1993 in Montreal, Quebec. Its business model has depended almost entirely on Egrifta since the 2010 approval [10]. The company has faced investor litigation related to forward-looking statements about the commercial trajectory of Egrifta following slower-than-projected market uptake in the first two years after launch.

Securities Litigation and Its Regulatory Implications

A 2013 securities class-action lawsuit filed in the U.S. District Court for the Southern District of New York alleged that Theratechnologies made materially misleading statements about Egrifta's commercial potential. The case was settled for approximately $7.25 million (USD) in 2015. This litigation is separate from FDA regulatory matters but shaped how the company communicated about the drug publicly and influenced subsequent investor disclosure language around clinical trial outcomes and regulatory timelines.

Milestone Payments, Licensing, and EMD Serono

Theratechnologies licensed U.S. Commercialization rights to EMD Serono (a Merck KGaA subsidiary) in 2010. EMD Serono handled U.S. Sales until 2016, when Theratechnologies reacquired full commercial rights. The reacquisition triggered a restructured royalty arrangement and milestone payment obligations. This licensing history means that patent enforcement and ANDA litigation during the EMD Serono period involved both companies as co-plaintiffs in some filings.

Regulatory Pathway Comparisons: Why Tesamorelin Took 12 Years from Phase 3 Data to Approval

The Falutz et al. Phase 3 data were published in 2007 [2], but FDA approval did not come until 2010. Three factors explain the gap. First, the FDA required a second confirmatory Phase 3 trial, which was not fully completed until late 2009. Second, the advisory committee's split vote in June 2010 required additional back-and-forth between the agency and Theratechnologies on label language and post-market commitments. Third, manufacturing inspections of the Montreal production facility required one cycle of remediation before the agency issued final approval [1].

This timeline matters for providers counseling patients about the drug's evidence base. The clinical data behind tesamorelin are more mature than those for many recently approved GLP-1 or peptide-based therapies, with nearly 18 years of published safety and efficacy data now available [2, 5, 11].

Current Clinical Practice Recommendations

The HIV Medicine Association and the Infectious Diseases Society of America acknowledge tesamorelin as the only FDA-approved pharmacological option for HIV-associated lipodystrophy in their clinical guidelines [16]. Lifestyle intervention and antiretroviral regimen optimization remain first-line steps; tesamorelin is recommended for patients with significant, confirmed visceral adiposity who have not responded adequately to those measures [16].

Prescribers should obtain a baseline IGF-1, fasting glucose, and HbA1c before initiating tesamorelin, repeat IGF-1 and fasting glucose at 3 months, and then at 6-month intervals during maintenance therapy [3, 12]. Patients with IGF-1 above the upper limit of normal at baseline represent a relative contraindication; the decision to prescribe requires documented clinical judgment and shared decision-making [3].

The recommended dose remains 2 mg subcutaneously once daily at bedtime, injected into the abdomen, rotating sites to minimize lipohypertrophy [3]. Benefits typically appear within 8 to 12 weeks; if no meaningful reduction in waist circumference or VAT (by imaging when available) occurs by 26 weeks, discontinuation should be considered [3].